KRAS/BRAF Mutation Analysis Kit
Cat Number: KRBR-RT50
The KRAS/BRAF Mutation Analysis Kit is a rapid, real-time PCR assay that detects clinically relevant mutations to help identify mCRC patients unlikely to benefit from EGFR-targeted therapy, enabling more informed and personalized treatment decisions.
- Below 1% Limit of Detection
- 50 tests per kit
- 2-hour turnaround time
- Works with FFPE and fresh frozen samples
- 13 Reactions per sample
- For research use (RUO) in the U.S
- For in vitro diagnostic use (IVD) in the European Union
The KRAS and BRAF genes encode key proteins in the EGFR signaling pathway, which regulates cell proliferation and survival. Mutations in KRAS—particularly in codons 12, 13, 61, 117, and 146—and in BRAF, such as the V600E mutation, are frequently found in cancers like metastatic colorectal cancer (mCRC), lung adenocarcinoma, and thyroid cancer. These mutations are associated with poor response to anti-EGFR antibody therapies, making comprehensive KRAS and BRAF mutation testing essential for guiding treatment decisions and improving patient outcomes.
The KRAS/BRAF Mutation Analysis Kit is a real-time PCR-based assay designed for the rapid, specific, and sensitive detection of clinically significant KRAS and BRAF mutations.
Utilizing allele-specific PCR and fluorescent hydrolysis probes, the assay preferentially amplifies mutant DNA—even in the presence of excess wild-type DNA—while an internal control ensures sample quality and amplification performance.
This robust and reliable assay delivers actionable results that support precision oncology and personalized treatment strategies.
The KRAS/BRAF Mutation Analysis Kit detects the following mutations in KRAS:
| Exon | Mutation | Nucleotide Change | Amino Acid Change | COSMIC ID |
| 2 | G12D | c.35G>A | Glycine (G) to Aspartic acid (D) | 521 |
| G12C | c.34G>T | Glycine (G) to Cysteine (C) | 516 | |
| G12S | c.34G>A | Glycine (G) to Serine (S) | 517 | |
| G12R | c.34G>C | Glycine (G) to Arginine (R) | 518 | |
| G12A | c.35G>C | Glycine (G) to Alanine (A) | 522 | |
| G12V | c.35G>T | Glycine (G) to Valine (V) | 520 | |
| G13D | c.38G>A | Glycine (G) to Aspartic acid (D) | 532 | |
| 3 | Q61H | c.183A>C & c.183A>T | Glutamine (Q) to Histidine (H) | 554 & 555 |
| Q61L | c.182A>T | Glutamine (Q) to Leucine (L) | 553 | |
| Q61R | c.182A>G | Glutamine (Q) to Arginine (R) | 552 | |
| 4 | K117N | c.351A>C & c.351A>T | Lysine (K) to Asparagine (N) | 19940 & 28519 |
| K117R | c.350A>G | Lysine (K) to Arginine (R) | 1178068 | |
| K117E | c.349A>G | Lysine (K) to Glutamic acid (E) | 1360831 | |
| A146T | c.436G>A | Alanine (A) to Threonine (T) | 19404 | |
| A146P | c.436G>C | Alanine (A) to Proline (P) | 19905 | |
| A146V | c.437C>T | Alanine (A) to Valine (V) | 19900 |
and BRAF:
| Exon | Mutation | Nucleotide Change | Amino Acid Change | COSMIC ID |
| 15 | V600E | c.1799T>A | Valine (V) to Glutamic acid (E) | 476 |
The KRAS/BRAF Mutation Analysis Kit follows a simple and easy to use process. It can be completed in 2 hours and follows a simple straightforward process.
EntroGenʼs KRAS/BRAF mutation screening panel requires a real-time PCR instrument capable of detecting VIC and FAM fluorescent probes.
This test includes reagents required for PCR amplification/detection, as well as validated reaction controls.
Columns and reagents for DNA isolation are not included. Genomic DNA from FFPE tissues can be extracted using EntroGen pureNA® Genomic DNA Isolation Kit.
Click to download lot-specific quality control data for your product:
